Chapters

Transcript

Video

SABCS 2022: Rachel Freedman, MD, MPH

Rachel Freedman, MD, MPH, shared results from the TBCRC 022 study where Neratinib in combination w/T-DM1 showed promising activity in patients w/heavily pre-treated HER2+ breast cancer metastatic to the central nervous system.

View Full Profile


Published

December 19, 2022

Created by

Dana-Farber